

Referências / References

1. a) F. Chast, “A history of drug discovery” em “The Practice of Medicinal Chemistry” 3ª edição, C-G Wermut, Editor, Academic Press, 2008, p. 1-62; b) F Chast, História contemporânea dos medicamentos, Piaget Editora, Lisboa, 1999; c) E. Ravina, The evolution of drug discovery, Wiley-VCH, 2011
2. Por limitação de espaço – 30 páginas segundo recomenda o edital - a bibliografia incluída cita os autores e o ano. O acesso direto se dá através do hyperlink colocado. Adicionalmente, no portal do **INCT-INOVAR** neste hiperlink é possível acessar a listagem de/ For limited space - 30 pages seconds recommends the writing - the included bibliography cites the authors and the year. Direct access is through the hyperlink placed. Additionally, the portal INCT- INOVAR this hyperlink may acessar the listing [Referências deste projeto](#).
3. A Kornberg, The two cultures: chemistry and biology, *Biochemistry* **1987**, *26*, 6888 DOI: [10.1021/bi00396a002](https://doi.org/10.1021/bi00396a002)
4. A Kornberg, *Braz J Med Biol Res* **1997**, *30*, 1379 [\[CrossRef\]](#)
5. *Annual Activities Report*: [2009](#); [2010](#); [2011](#); [2012](#); [2013](#)
6. No portal-web do **INCT-INOVAR** na aba INCT-INOVAR Proposta-2014 (*Proposal INCT 2014*) em “Material Suplementar” (see *Supplementary Material*) está disponível documento que descreve a participação da empresa/ is available document describing the company's participation.
7. [Annual Activities Report 2013](#)
8. Meibohm, B., Derendorf, Pharmacokinetic/Pharmacodynamic Studies in Drug Product Development. *Journal of Pharmaceutical Sciences* 91(1): 18-31, 2002. DOI: [10.1002/jps.1167](https://doi.org/10.1002/jps.1167)
9. Danhof, M. et al. Mechanism-based pharmacokinetic- pharmacodynamic (PK-PD) modeling in translational drug research. *Trends in Pharmacological Sciences* 29(4): 186, 191, 2008. DOI:[10.1016/j.tips.2008.01.007](https://doi.org/10.1016/j.tips.2008.01.007)
10. Breimer, D.D., PK/PD Modelling and Beyond: Impact on Drug Development. *Pharmaceutical Research* 25(12): 2720-2722, 2008. DOI: [10.1007/s11095-008-9717-x](https://doi.org/10.1007/s11095-008-9717-x)
11. Danhof, M. et al., Mechanism-based pharmacokinetic/pharmacodynamic modeling for the prediction of in vivo drug concentration-effect relationships – application in drug candidate selection and lead optimization. In: *Comprehensive Testa, B. & Van De Waterbeemd, H. Ed. Medicinal Chemistry II, Part 5. Elsevier, pp. 885–908, 2007*
12. Rajman, I PK/PD modelling and simulations: utility in drug development. *Drug Discovery Today* 13(7/8): 341-346, 2008. DOI: [10.1016/j.drudis.2008.01.003](https://doi.org/10.1016/j.drudis.2008.01.003)
13. Agoram, B M., Martin, S W., van der Graaf, P.H., The role of mechanism-based pharmacokinetic–pharmacodynamic (PK–PD) modelling in translational research of biologics. *Drug Discovery Today* 12 (23/24):1018-1024, 2007 DOI: [10.1016/j.drudis.2007.10.002](https://doi.org/10.1016/j.drudis.2007.10.002)
14. Miller, R. et al., How Modeling and Simulation Have Enhanced Decision Making in New Drug Development. *Journal of Pharmacokinetics and Pharmacodynamics* 32(2): 185-197, 2005. DOI: [10.1007/s10928-005-0074-7](https://doi.org/10.1007/s10928-005-0074-7)
15. No item 5 (p. 18) deste projeto do **INCT-INOVAR**, estão listados os líderes dos laboratórios associados constituindo-se por: 07 pesquisadores 1A; 04 pesquisadores 1B; 01 pesquisador 1C; 06 pesquisadores 1D e 10 pesquisadores nível 2, bolsistas de produtividade em pesquisa do CNPq / In section 5 (. P 18) of this INCT- INOVAR project are listed the leaders of associated laboratories

* A numeração é a mesma do projeto/ the numbers are the same of the project

- constituting by 07 CNPq Fellows 1A; 04 1B; 01 1C; 06 CNPq Fellows 1D and 10 level 2.
16. As empresas farmacêuticas que apóiam essa proposta são/ The pharmaceutical companies that support this proposal are [Cristália Produtos Químicos Farmacêuticos Ltda](#), [Sanofi-Aventis Farmacêutica Ltda.](#), [Libbs Farmacêutica](#); farmoquímica: [Nortec Química](#).
 17. [Cemsa](#), [inVitro Cells](#), [Biotech Cells](#).
 18. A equipe do [SIQUIM](#), UFRJ, realiza estudos prospectivos do mercado farmacêutico de genéricos no País subsidiando a eleição das oportunidades em fármacos genéricos para estudos sintéticos/ The staff of [SIQUIM](#), UFRJ, performs prospective studies of the pharmaceutical market of generics in order to help the choice of the best opportunities in generic drugs to synthetic studies
 19. Esta proposta de INCT engloba distintos níveis de parcerias com empresas farmacêuticas e farmoquímica sendo algumas apenas apoiadoras da proposta enquanto outras participam efetivamente do desenvolvimento de subprojetos como será mencionado no texto oportunamente / This INCT proposal encompasses different levels of partnerships with pharmaceutical companies and pharmaceutical chemistry and some just supporters of the proposal while others participate effectively in the development of subprojects as will be mentioned in the text timely .
 20. O comitê de consultores científicos (SAC; Scientific Advisory Committee) será formado pelos pesquisadores indicados no item 12 deste documento / The scientific advisory committee (SAC; Scientific Advisory Committee) will be formed by the researchers indicated in item 12 of this document.
 21. a) RM Rydzewski, Real world drug discovery: a chemist's guide to biotech and pharmaceutical research, Elsevier, Ltd, 2008; R Ng Drugs: from discovery to approval, Wiley-Blackwell, 2009; b) CJ Tralau-Stewart et al., UK Academic drug discovery, Nature Rev. Drug Discov. 2013, 13, 15; doi:[10.1038/nrd4200](#); c) H S Kirkegaard, F Valentin, Academic drug discovery centres: the economic and organisational sustainability of an emerging model, DDT Available online 19 June 2014, DOI: [10.1016/j.drudis.2014.06.011](#); d) A A Toole, The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry, Res. Policy 2012, 41, 1; doi:[10.1016/j.respol.2011.06.004](#); e) JW Scannell, et al., Diagnosing the decline in pharmaceutical R&D efficiency, Nature Rev. Drug Discov. 2012, 11, 191; doi:[10.1038/nrd3681](#); f) M Goldman, The Innovative Medicines Initiative: A European Response to the Innovation Challenge, Clinical Pharmacology & Therapeutics 2012, 91, 418 doi:[10.1038/clpt.2011.321](#); g) M Goldman, Reflections on the Innovative Medicines Initiative, Nature Rev. Drug Discov. 2011, 10, 321; doi:[10.1038/nrd3434](#); h) F Pammolli et al., The productivity crisis in pharmaceutical R&D, Nature Rev. Drug Discov. 2011, 10, 428 ; doi:[10.1038/nrd3405](#) i) M Williams, Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences? JPET 2011, 336, 3; doi: [10.1124/jpet.110.171751](#); j) SM Paul et al., How to improve R&D productivity: the pharmaceutical industry's grand challenge, Nature Rev. Drug Discov. 2010, 9, 203; doi:[10.1038/nrd3078](#) k) - R Kneller, The importance of new companies for drug discovery: origins of a decade of new drugs. Nature Rev. Drug Discov. 2010, 9, 867; doi:[10.1038/nrd3251](#); l) M R Barnes et al. Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery, Nature Rev. Drug Discov. 2009, 8, 701; doi:[10.1038/nrd2944](#) ; m) B Hughes, Harnessing open innovation, Nature Rev. Drug Discov. 2009, 8, 344; [10.1038/nrd2891](#); n) B Munos, Lessons for 60 years of pharmaceutical innovation, Nature Rev. Drug Discov. 2009, 8, 959 doi:[10.1038/nrd2961](#); o) PG Wyatt, The emerging academic drug-discovery sector. Future Med. Chem. 2009, 1, 1013; p) CJ Tralau-Stewart, CA Wyatt, DE Kleyn, A

* A numeração é a mesma do projeto/ the numbers are the same of the project

- Ayad, Drug discovery: new models for industry–academic partnerships, *Drug Discov Today* 2009, 14, 95. Doi:[10.1016/j.drudis.2008.10.003](https://doi.org/10.1016/j.drudis.2008.10.003)
22. Verli, H.; Barreiro, E.J. Um paradigma da química medicinal: a flexibilidade dos ligantes e receptores, *Quim Nova* 2005, 28, 95 [[CrossRef](#)]
23. R. T. Sudo, et al., “Thienylhydrazon with digitalis-like properties (positive inotropic effects)”, Patent [US7091238](#) (15 de Agosto de 2006), WO 200078754, AU 200056287, EP 1532140, CA 2384525, PCT/US2000/017024
24. As publicações correspondentes aos resultados obtidos com o composto **LASSBio-294** estão disponíveis no / publications corresponding to the results obtained with the compound LASSBio-294 available in [hiperlink.](#):
- a) JR Azevedo, J-J Letourneau, F Espitalier, MI Ré, Solubility of a new cardioactive prototype drug in ionic liquids, *J. Chem. Eng. Data*, **59**, 1766–1773 (2014). Doi: 10.1021/je4009624 [[CrossRef](#)]
- b) JS da Silva, SL Pereira, RC Maia, SS Landgraf, C Caruso-Neves, AE Kümmerle, CAM Fraga, EJ Barreiro, RT Sudo, G Zapata-Sudo, *N*-acylhydrazone improves exercise intolerance in rats submitted to myocardial infarction by the recovery of calcium homeostasis in skeletal muscle, *Life Sciences*, **94**, 30–36 (2014). Doi: 10.1016/j.lfs.2013.11.012 [[CrossRef](#)]
- c) FN Costa, FF Ferreira, TF da Silva, EJ Barreiro, LM Lima, D Braza, RC Barroso, Structure re-determination of LASSBio-294 – a cardioactive compound of the *N*-acylhydrazone class – using X-ray powder diffraction data, *Powder Diffraction*, **28**, S491-S509 (2013). Doi: 10.1017/S0885715613000808 [[CrossRef](#)]
- d) ACB Torres, PR Nasciutti, IP Bittar, RV Muniz, TM Guimarães, V Oliveira, AB Fraga, RO Alves, Pharmacological profile of the cardioactive prototypes LASSBio-294 and LASSBio-897: A comparative preliminary study of their metabolites' effects on myocardial contraction, *J. Vet. Intern. Med.*, **27**, 647-647 (2013). [[CrossRef](#)]
- e) CM Leal, SL Pereira, AE Kümmerle, DM Leal, R Tesch, CMR Sant’Anna, CAM Fraga, EJ Barreiro, RT Sudo, G Zapata-Sudo, Antihypertensive profile of 2-thienyl-3,4-methylenedioxybenzoylhydrazone is mediated by activation of the A_{2A} adenosine receptor, *Eur. J. Med. Chem.*, **55**, 49–57 (2012). Doi: 10.1016/j.ejmech.2012.06.056 [[CrossRef](#)]
- f) RC Braga, VM Alves, CAM Fraga, EJ Barreiro, V de Oliveira, CH Andrade, Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone, *J. Mol. Model.*, **18**, 2065–2078 (2012). Doi: 10.1007/s00894-011-1219-9 [[CrossRef](#)]
- g) RC Braga, ACB Tôrres, CB Persiano, RO Alves, CAM Fraga, EJ Barreiro, V de Oliveira, Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LC–MS/MS: Application for a pharmacokinetic study, *Journal of Pharmaceutical and Biomedical Analysis*, **55**, 1024-1030 (2011). Doi: 10.1016/j.jpba.2011.02.031 [[CrossRef](#)]
- h) A G M Fraga, L L da Silva, CAM Fraga, EJ Barreiro, CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes

- and human recombinant CYP enzymes, *Eur. J. Med. Chem.*, **46**, 349-355 (2011). Doi: 10.1016/j.ejmech.2010.11.024 [[CrossRef](#)]
- i) DG Costa, JS da Silva, AE Kummerle et al., LASSBio-294, A compound with inotropic and lusitropic activity, decreases cardiac remodeling and improves Ca²⁺ influx into sarcoplasmic reticulum after myocardial infarction, *Am. J. Hypertension*, **23**, 1220-1227 (2010). Doi: 10.1038/ajh.2010.157 [[CrossRef](#)]
- j) FCF Brito, AE Kummerle, C Lugnier et al., Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A₂ synthesis inhibition, *Eur. J. Pharmacol.*, **638**, 5-12 (2010). Doi: 10.1016/j.ejphar.2010.04.003 [[CrossRef](#)]
- k) EO Carneiro, CH Andrade, RC Braga et al., Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294, *Bioorg. Med. Chem. Lett.*, **20**, 3734-3736 (2010). Doi: 10.1016/j.bmcl.2010.04.073 [[CrossRef](#)]
- l) L Pol-Fachin, CAM Fraga, EJ Barreiro et al., Characterization of the conformational ensemble from bioactive *N*-acylhydrazone derivatives, *J. Mol. Graphics & Modelling*, **28**, 446-454 (2010). Doi: 10.1016/j.jmgm.2009.10.004 [[CrossRef](#)]
- m) AE Kummerle, JM Raimundo, CM Leal et al., Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene *N*-acylhydrazone derivatives, *Eur. J. Med. Chem.*, **44**, 4004-4009 (2009). Doi: 10.1016/j.ejmech.2009.04.044 [[CrossRef](#)]
- n) AG Silva, G Zapata-Sudo, AE Kummerle et al., Synthesis and vasodilatory activity of new *N*-acylhydrazone derivatives, designed as LASSBio-294 analogues, *Bioorg. Med. Chem.*, **13**, 3431-3437 (2005). Doi: 10.1016/j.bmc.2005.03.003 [[CrossRef](#)]
- o) G Zapata-Sudo, RT Sudo, PA Maronas et al., Thienylhydrazone derivative increases sarcoplasmic reticulum Ca²⁺ release in mammalian skeletal muscle, *Eur. J. Pharmacol.*, **470**, 79-85 (2003). Doi: 10.1016/S0014-2999(03)01757-6 [[CrossRef](#)]
- p) EJ Barreiro, Strategy of molecular simplification in rational drug design: The discovery of a new cardioactive agent, *Quim. Nova*, **25**, 1172-1180 (2002). Doi: 10.1590/S0100-40422002000700018 [[CrossRef](#)]
- q) CLM Silva, F Noel, EJ Barreiro, Cyclic GMP-dependent vasodilatory properties of LASSBio 294 in rat aorta, *Br. J. Pharmacol.*, **135**, 293-298 (2002). Doi: 10.1038/sj.bjp.0704473 [[CrossRef](#)]
- r) H Gonzalez-Serratos, RZ Chang, EFR Pereira et al., A novel thienylhydrazone, (2-thienylidene)3,4-methylenedioxybenzoylhydrazine, increases inotropism and decreases fatigue of skeletal muscle, *J. Pharmacol. Exp. Ther.*, **299**, 558-566 (2001). [[CrossRef](#)]

- s) RT Sudo, G Zapata-Sudo, EJ Barreiro, The new compound, **LASSBio 294**, increases the contractility of intact and saponin-skinned cardiac muscle from Wistar rats, *Br. J. Pharmacol.*, **134**, 603-613 (2001) Doi: 10.1038/sj.bjp.0704291 [[CrossRef](#)]
- t) PC Lima, LM Lima, KCM Silva et al., Synthesis and analgesic activity of novel *N*-acylarylhydrazones and isosters, derived from natural safrole, *Eur. J. Med. Chem.*, **35**, 187–203 (2000). Doi: 10.1016/S0223-5234(00)00120-3 [[CrossRef](#)]
25. a) Donath, M.Y.; Targeting inflammation in the treatment of type 2 diabetes: time to start, *Nature rev. Drug Discov.* 2014, 13, 465 [[CrossRef](#)]; b) Manabe, I.; Chronic Inflammation Links Cardiovascular, Metabolic and Renal Diseases, *Circulation Journal* 2011, 75, 2739-2748 [[CrossRef](#)]; c) Couzin-Frankel, J.; Inflammation Bares a Dark Side, *Science* 2010,;330, 1621 [[CrossRef](#)]; d) Schottenfeld, D.; Beebe-Dimmer, J.; Chronic Inflammation: A Common and Important Factor in the Pathogenesis of Neoplasia, *CA Cancer J Clin* 2006; 56, 69 [[CrossRef](#)].
26. Rocco, P. R. M.; Xisto, D. G.; Diniz, M. F. F. M.; Almeida, R. N.; Luciano, M. N.; Medeiros, I. A.; Cavalcanti, B. C.; Ferreira, J. R. O.; Moraes, M. O.; Costa-Lotufo, L. V.; Pessoa, C.; Costa, T. D.; Cattani, V. B.; Barreiro, E. J.; Lima, L. M., **LASSBio-596**: da descoberta aos ensaios pré-clínicos, *Rev. Virtual Quim.* 2010, 2, 10 [[Link](#)]
27. Kumar, S. Boehm, J.; Lee, J. C.; p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases, *Nature Rev. Drug Discov.* 2003, 2, 717 [[CrossRef](#)]
28. Błajacka, K.; Borgstrom, A.; Arcaro, A.; Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets, *Current Drug Targets* 2011, 12, 1389 [[CrossRef](#)];
29. Ferguson, F. G. Milne, L.; Kulkarni, S.; Sasaki, T.; Walker, S.; Andrews, S.; Crabbe, T.; Finan, P.; Jones, G.; Jackson, S.; Camps, M.; Rommel, C.; Wymann, W.; Hirsch, E.; Hawkins, P.; Stephens, I. PI(3)Kγ has an important context-dependent role in neutrophil chemokinesis, *Nature Cell Biology* 2006, 9, 86 doi:[10.1038/ncb1517](#)
30. Fukao, T.; Tanabe, M.; Terauchi, Y.; Ota, T.; Matsuda, S.; Asano, T.; Kadowaki, T.; Takeuchi, T.; Koyasu, S., PI3K-mediated negative feedback regulation of IL-12 production in DCs, *Nature Immunol.* 2002, 3, 875. doi:[10.1038/ni825](#)
31. Ward, S. G.; Finan, P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents, *Current Opinion in Pharmacology* 2003, 3, 426 [[CrossRef](#)]
32. Medina-Tato, D. A.; Ward, S. G.; Watson, M. L., Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond, *Immunology* 2007, 121, 448 [[CrossRef](#)];
33. Chung, K. F., p38 Mitogen-Activated Protein Kinase Pathways in Asthma and COPD, *Chest* 2011, 139, 1470 [[CrossRef](#)]
34. a) Srisantharajah, S. Hamblin, N.; Worsley, S.; Calver, A. R.; Hessel, E. M.; Amour, A., Targeting phosphoinositide 3-kinase δ for the treatment of respiratory diseases, *Annals of the New York Academy of Sciences* 2013, 1280, 35. [[CrossRef](#)]; b) MacNee, W.; Allan, R. J.; Jones, I.; de Salvo, M. C.; Tan, L. F., Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial, *Thorax* 2013, 68, 738 [[CrossRef](#)]; c) Barnes, P. J., Corticosteroid resistance in patients with asthma and

- chronic obstructive pulmonary disease, Journal of Allergy and Clinical Immunology 2013, 131, 636 DOI: [10.1016/j.jaci.2012.12.1564](https://doi.org/10.1016/j.jaci.2012.12.1564)
35. Guariguata, L.; Whitting, D. R.; Hambleton, I.; Beagley, J.; Linnenkamp, U.; Shaw, J. E., Global estimates of diabetes prevalence for 2013 and projections for 2035, Diabetes Research and Clinical Practice 2014, 103, 137 [[CrossRef](#)]
36. Vide em [[Hiperlink](#)]
37. Poitout, V.; Robertson, R. P., Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity, Endocrinology 2002, 143, 339 [[PubMed](#)]
38. a) Bailes, B. K., Diabetes Mellitus and its Chronic Complications, AORN Journal 2002, 76, 265 [[CrossRef](#)]; b) Fowler, M. J., Microvascular and Macrovascular Complications of Diabetes, Clinical Diabetes 2008, 26, 77 [[CrossRef](#)]
39. Barreiro, E. J. et al., Composto sulfonilidrazônico, processo de obtenção do composto sulfonilidrazônico e composições farmacêuticas, BR 1020130126462, 22/05/2013.
40. Zapata-Sudo, G.; Lima, L. M.; Pereira, S. M.; Trachez, M.; da Costa, F. P.; Souza, B.; Monteiro, C. E. S.; Romeiro, N. C.; D'Andrea, E. D.; Sudo, R. T.; Barreiro, E. J.; Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists, Current Topics in Medicinal Chemistry 2012, 12, 2037 [[CrossRef](#)]
41. Viegas-Junior et al., 2007 [[CroosRef](#)]
42. Karagiannis, T.; Paschos, P.; Paletas, K.; Mathews, D. R.; Tsapas, A., Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis, BMJ 2012, 344, e1369 doi: [dx.doi.org/10.1136/bmj.e1369](https://doi.org/10.1136/bmj.e1369)
43. Barbosa, M. L. C.; Lima, L. M.; Tesch, R.; Sant'Anna, C. M. R.; Totzke, F.; Kubbutat, M. I. H. G.; Schaechtele, C.; Laufer, S. A.; Barreiro, E. J., Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors, European Journal of Medicinal Chemistry , 71, 1 DOI: [10.1016/j.ejmech.2013.10.058](https://doi.org/10.1016/j.ejmech.2013.10.058)
44. Fraga, C. A. M., Barreiro, E. J., Curr Drug Therapy 2008, 3, 1 [[CrossRef](#)]
45. Barreiro, E. J. et al., Compostos 2-cloro-4-anilinoquinazolínicos inibidores de proteína cinases, composições farmacêuticas compreendendo os emsmos, processo para sua produção e método para inibição de tirosina, INPI-BR 1020130018090 de 24/01/2013.
46. Resultados preliminares em outra série de compostos oriundos do / Preliminary results in another series of compounds from **LASSBio**, vide/see: Do Amaral, D. N.; Cavalcanti, B. C.; Bezerra, D. P.; Ferreira, P. M. P.; Castro, R. P.; Sabino, J. R.; Machado, C. M. L.; Chamas, R.; Pessoa, C.; Sant'Anna, C. M. R.; Barreiro, E. J.; Lima, L. M., Docking, Synthesis and Antiproliferative Activity of N-Acylhydrazone Derivatives Designed as Combretastatin A4 Analogues, PLoS ONE 2014, 9, e85380 DOI: [10.1371/journal.pone.0085380](https://doi.org/10.1371/journal.pone.0085380)
47. Barreiro, E. J.; Lima, L. M., Bioisosterism: a useful strategy for molecular modification and drug design, Current Medicinal Chemistry 2005, 12, 23 [[CrossRef](#)]

48. No portal-web do atual **INCT-INOVAR** na aba Proposta-2014, em *Material Suplementar*, está disponível cópia escaneada do termo firmado pelas duas instituições ([hiperlink](#)).
49. Zolot, R. S.; Basu, S.; Million, R. P., Antibody–drug conjugates, *Nature Rev. Drug Discov.* 2013, 12, 259 doi:[10.1038/nrd3980](#)
50. A recente aprovação do fármaco conjugado de brentuximab (Adcetris^R) suporta a proposta, vide: Flygare, J. A.; Pillow, T. H.; Aristoff, P., Antibody-Drug Conjugates for the Treatment of Cancer, *Chemical Biology Drug Design* 2013, 81, 113 doi: [10.1111/cbdd.12085](#)
51. Neidle, S.; Thurston, D. E., chemical approaches to the discovery and development of cancer therapies, *Nature Rev Cancer* 2005, 5, 285 doi:[10.1038/nrc1587](#)
52. El-Sayed, N. M.; Myler, P. J.; Blandin, G.; Berriman, M.; Crabtree, J.; Aggarwal, G.; Caler, E.; Renaud, H.; Worthey, E. A.; Hertz-Fowler, C.; Ghedin, E.; Peacock, C.; Bartholomeu, D. C.; Haas, B. J.; Tran, A-N.; Wortmann, J. R.; Alsmark, U. C. M.; Angiuoli, S.; Anupama, A.; Badger, J.; Bringaud, F.; Cadag, E.; Carlton, J. M.; Cerqueira, G. C.; Creasy, T.; Deicher, A. L.; Djikeng, A.; Embley, T. M.; Hauser, C.; Ivens, A. C.; Kummerfeld, S. K.; Leal, J. B. P.; Nilsson, D.; Peterson, J.; Salzberg, S. L.; Shallom, J.; Silva, J. C.; Sundaram, J.; Westenberger, S.; White, O.; Melville, S. E.; Donelson, J. E.; Andersson, B.; Stuart, K. D.; Hall, N., Comparative Genomics of Trypanosomatid Parasitic Protozoa, *Science* 2005, 309, 404 [[CrossRef](#)]
53. Brennan, A.; Gualdrón-López, M.; Coppens, I.; Rigden, D. J.; Ginger, M. L.; Michels, P. A. M., Autophagy in parasitic protists: Unique features and drug targets, *Molecular and Biochemical Parasitology* 2011, 177, 83 [[CrossRef](#)]
54. Depósito de patente PCT/BR2013/000276; WO2014019044 A1.
55. http://www.mct.gov.br/upd_blob/0218/218981.pdf
56. Escritório [Remer, Vilaça & Nogueira](#)
57. Vide em [\[hiperlink\]](#)
58. [\[Hiperlink\]](#)
59. a) Volkow, N. D.; Fowler, J. S.; Wang, G. J.; Swanson, J. M.; *Mol Psychiatry.* 2004, 9, 557-69 [[CrossRef](#)]; b) Shorter, D.; Kosten, T.R.; *BMC Medicine* 2011, 9, 119-127 [[CrossRef](#)]
60. a) Yao L.; Fan P.; Arolfo M.; Jiang Z.; Foster-Olive M.; Zablocki J.; Sun H.-L.; Chu N.; Lee J.; Kim H.-Y.; Leung K.; Shryock J.; Blackburn B.; Diamond I. Inhibition of aldehyde dehydrogenase-2 suppresses cocaine seeking by generating THP, a cocaine use–dependent inhibitor of dopamine synthesis. *Nature Med.* 16:1024-1028, 2010. doi: 10.1038/nm.2200 [[CrossRef](#)]; b) Keung W-M.; Klyosov A.A.; Vallee B.L. Daidzin inhibits mitochondrial aldehyde dehydrogenase and suppresses ethanol intake of Syrian golden hamsters. *Proc. Natl. Acad. Sci. USA* 94:1675–1679, 1997. doi: 10.1073/pnas.94.5.1675 [[CrossRef](#)]
61. Cheung T.H.C., Loriaux A.L., Weber S.M., Chandler K.N., Lenz J.D., Schaan R.F., Mach R.H., Luedtke R.R., Neisewander J.L. Reduction of Cocaine Self-Administration and D3 Receptor-Mediated Behavior by Two Novel Dopamine D3 Receptor-Selective Partial Agonists, OS-3-106 and WW-III-55. *J. Pharmacol. Exp. Ther.* 347:410-423, 2013. doi: 10.1124/jpet.112.202911 [[CrossRef](#)]

62. a) Harvey R.J., Yee, B.K. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. *Nature Rev. Drug Discov.* 12:866-885, 2013. doi: 10.1038/nrd3893 [[CrossRef](#)];
63. Matuskey D., Gallezot J., Pittman B., Williams W., Wanyiri J., Gaiser E., Lee D.E., Hannestad J., Lim K., Zheng M., Lin S., Labaree D., Potenza M.N., Carson R.E., Malison R.T., Ding Y. Dopamine D3 receptor alterations in cocaine-dependent humans imaged with [¹¹C](+)-PHNO. *Drug Alcohol Depend.* 139:100–105, 2014. doi: 10.1016/j.drugalcdep.2014.03.013 [[CrossRef](#)]
64. Dias, L. C.; Vieira, A. S. ; Barreiro, E.Jj., Processo de obtenção de atorvastatina cálcica utilizando novos intermediários e atorvastatina assim obtida, INPI depósito: 018110015039 , 25/04/2011.
65. A Cristália Produtos Químicos Farmacêuticos Ltda é uma indústria farmacêutica integrante da equipe associada ao projeto e terá sob sua responsabilidade e ônus os estudos de desenvolvimento galênico/farmacotécnico dos novos compostos-protótipos descobertos, além de apoiar os estudos de fase clínica para os compostos do **INCT-INO FAR**, quando de seu interesse / Cristália Produtos Químicos Farmacêuticos Ltda is a pharmaceutical industry team member associated with the project and will be responsible and burden studies of galenic development / pharmacotechnical of newly discovered compounds prototypes, and support the clinical phase studies for compounds INCT-INO FAR, when of your interest
66. São indicados nesta listagem apenas os pesquisadores líderes e suas áreas de atuação no **INCT-INO FAR**. Cada laboratório associado tem sua equipe (bolsistas pós-doutores e pós-graduandos) que serão oportunamente incorporados e atuarão sob responsabilidade de supervisão do pesquisador líder da equipe do laboratório associado participante /are indicated in this listing only the leading researchers and their areas of activity in INCT-INO FAR. Each has its associated laboratory staff (post-doctoral fellows and graduate students) that will be incorporated in due course and will act under the responsibility of supervising the researcher leading the associated laboratory participating team .
67. [Annual Activity Report 2013 - p. 43](#)
68. Na data em que redigimos este projeto (01/09/2014) temos convênio firmado com a Secretaria Municipal de Educação da cidade do Rio de Janeiro para atuarmos em escolas municipais da região do entorno da Cidade Universitária da ilha do Fundão /On the date that drafted this project (09.01.2014) have signed an agreement with the City Department of Education of the city of Rio de Janeiro for maneuver in municipal schools in the surrounding area of the Campus of the Federal University of Rio de Janeiro on the island of Fundão.
69. *Annual Activities Report*: [2009](#); [2010](#); [2011](#); [2012](#); [2013](#)
70. Todos os membros indicados para comporem o Comitê de Consultores Externos (Scientific Advisory Committee) manifestaram formalmente sua concordância. Cópias estão disponíveis no portal-web do **INCT-INO FAR** em *Proposta-2014* / All members appointed to compose the Scientific Advisory Committee (SAC), formally expressed their agreement. Copies are available in INCT-INO FAR web-site in Proposal-2014 (Supplementary Material).

* A numeração é a mesma do projeto/ the numbers are the same of the project